Skip to main content

Table 2 Relationship between 6MWD and Same-visit Biomarkers

From: Treatment-related biomarkers in pulmonary hypertension patients on oral therapies

Biomarkera Estimate Standard error p-value
ET-1 (N = 55) − 44.94 18.19 0.016
NTproBNP (N = 55)    
  Log(NTproBNP + 1) ≤ 5.5, per 1 unit increase − 4.67 7.37 0.53
  Log(NTproBNP + 1) > 5.5, per 1 unit increase − 31.25 8.71 0.0006
RDW (N = 55) − 184.04 71.37 0.012
cGMP (N = 54) 1.78 10.57 0.87
SNO-Hb (N = 50) 1303.27 2822.37 0.64
cGMP/NTproBNP ratio (N = 53)    
   Log(cGMP/NTproBNP + 1) ≤ 0.3, per 1 unit increase 180.89 82.37 0.032
   Log(cGMP/NTproBNP + 1) > 0.3, per 1 unit increase 27.23 27.30 0.32
NO2 (N = 49) 7.47 6.75 0.28
SDMA (N = 54)    
  Log(SDMA + 1) ≤ 6, per 1 unit increase 5.82 46.70 0.90
  Log(SDMA + 1) > 6, per 1 unit increase − 46.96 25.25 0.067
ADMA (N = 54)b    
  ADMA, PAH on treatment with ERA − 0.22 0.087 0.012
  ADMA, PAH on treatment with PDE5i − 0.035 0.11 0.75
  ADMA, PAH on treatment with ERA + PDE5i 0.098 0.088 0.27
  1. aAll biomarkers are transformed as log(biomarker + 1) with the exception of ADMA. All models were adjusted for age
  2. bInteraction p = 0.038